218 related articles for article (PubMed ID: 8099502)
1. High-dose chemotherapy and hematopoietic stem cell rescue in patients with relapsed Hodgkin's disease.
Schmitz N; Glass B; Dreger P; Haferlach T; Horst HA; Ollech-Chwoyka J; Suttorp M; Gassmann W; Löffler H
Ann Hematol; 1993 May; 66(5):251-6. PubMed ID: 8099502
[TBL] [Abstract][Full Text] [Related]
2. Favorable outcome of patients with relapsed or refractory Hodgkin's disease treated with high-dose chemotherapy and stem cell rescue at the time of maximal response to conventional salvage therapy (Dex-BEAM).
Josting A; Kàtay I; Rueffer U; Winter S; Tesch H; Engert A; Diehl V; Wickramanayake PD
Ann Oncol; 1998 Mar; 9(3):289-95. PubMed ID: 9602263
[TBL] [Abstract][Full Text] [Related]
3. High-dose chemotherapy with or without total body irradiation followed by autologous bone marrow and/or peripheral blood stem cell transplantation for patients with relapsed and refractory Hodgkin's disease: results in 85 patients with analysis of prognostic factors.
Nademanee A; O'Donnell MR; Snyder DS; Schmidt GM; Parker PM; Stein AS; Smith EP; Molina A; Stepan DE; Somlo G
Blood; 1995 Mar; 85(5):1381-90. PubMed ID: 7858268
[TBL] [Abstract][Full Text] [Related]
4. Autologous progenitor cell transplantation: prior exposure to stem cell-toxic drugs determines yield and engraftment of peripheral blood progenitor cell but not of bone marrow grafts.
Dreger P; Klöss M; Petersen B; Haferlach T; Löffler H; Loeffler M; Schmitz N
Blood; 1995 Nov; 86(10):3970-8. PubMed ID: 7579368
[TBL] [Abstract][Full Text] [Related]
5. High-dose BEAM chemotherapy with autologous peripheral blood progenitor-cell transplantation for unselected patients with primary refractory or relapsed Hodgkin's disease.
Argiris A; Seropian S; Cooper DL
Ann Oncol; 2000 Jun; 11(6):665-72. PubMed ID: 10942053
[TBL] [Abstract][Full Text] [Related]
6. Salvage chemotherapy with mini-BEAM for relapsed or refractory Hodgkin's disease prior to autologous peripheral blood stem cell transplantation.
Fernández-Jiménez MC; Canales MA; Ojeda E; de Bustos JG; Aguado MJ; Hernández-Navarro F
Haematologica; 1999 Nov; 84(11):1007-11. PubMed ID: 10553161
[TBL] [Abstract][Full Text] [Related]
7. High-dose sequential chemotherapy followed by autologous stem cell transplantation in relapsed and refractory aggressive non-Hodgkin's lymphoma: results of a multicenter phase II study.
Josting A; Sieniawski M; Glossmann JP; Staak O; Nogova L; Peters N; Mapara M; Dörken B; Ko Y; Metzner B; Kisro J; Diehl V; Engert A
Ann Oncol; 2005 Aug; 16(8):1359-65. PubMed ID: 15939712
[TBL] [Abstract][Full Text] [Related]
8. High-dose chemotherapy followed by autologous hematopoietic rescue for Hodgkin's disease patients following first relapse after chemotherapy.
Bierman PJ; Anderson JR; Freeman MB; Vose JM; Kessinger A; Bishop MR; Armitage JO
Ann Oncol; 1996 Feb; 7(2):151-6. PubMed ID: 8777171
[TBL] [Abstract][Full Text] [Related]
9. Intensive conditioning regimen of etoposide (VP-16), cyclophosphamide and carmustine (VCB) followed by autologous hematopoietic stem cell transplantation for relapsed and refractory Hodgkin's lymphoma.
Benekli M; Smiley SL; Younis T; Czuczman MS; Hernandez-Ilizaliturri F; Bambach B; Battiwalla M; Padmanabhan S; McCarthy PL; Hahn T
Bone Marrow Transplant; 2008 Apr; 41(7):613-9. PubMed ID: 18071290
[TBL] [Abstract][Full Text] [Related]
10. High-dose cyclophosphamide, etoposide and BCNU (CVB) with autologous stem cell rescue in malignant lymphomas.
Patti C; Majolino I; Scimè R; Indovina A; Vasta S; Liberti G; Gentile S; Santoro A; Pisa R; Caronia F
Eur J Haematol; 1993 Jul; 51(1):18-24. PubMed ID: 8348940
[TBL] [Abstract][Full Text] [Related]
11. Phase I/II study of high-dose cyclophosphamide, etoposide and cisplatin followed by autologous bone marrow or peripheral blood stem cell transplantation in patients with poor prognosis Hodgkin's disease or non-Hodgkin's lymphoma.
Klumpp TR; Mangan KF; Glenn LD; Malaspina DR; Cropper T; Mullaney M; Macdonald JS
Bone Marrow Transplant; 1993 Oct; 12(4):337-45. PubMed ID: 7506091
[TBL] [Abstract][Full Text] [Related]
12. High-dose therapy followed by autologous peripheral-blood stem-cell transplantation for patients with Hodgkin's disease and non-Hodgkin's lymphoma using unprimed and granulocyte colony-stimulating factor-mobilized peripheral-blood stem cells.
Nademanee A; Sniecinski I; Schmidt GM; Dagis AC; O'Donnell MR; Snyder DS; Parker PM; Stein AS; Smith EP; Molina A
J Clin Oncol; 1994 Oct; 12(10):2176-86. PubMed ID: 7523609
[TBL] [Abstract][Full Text] [Related]
13. Treatment of refractory and relapsed Hodgkin's disease: intensive chemotherapy and autologous bone marrow or peripheral blood stem cell support.
Hurd DD; Haake RJ; Lasky LC; Christiansen NP; McGlave PB; Bostrom B; Levine EG; Weisdorf DJ; Kim TH; Peterson BA
Med Pediatr Oncol; 1990; 18(6):447-53. PubMed ID: 1978232
[TBL] [Abstract][Full Text] [Related]
14. Autologous stem-cell transplantation for poor-risk and relapsed intermediate- and high-grade non-Hodgkin's lymphoma.
Nademanee A; Molina A; Dagis A; Snyder DS; O'Donnell MR; Parker P; Stein A; Smith E; Planas I; Kashyap A; Spielberger R; Fung H; Krishnan A; Bhatia R; Wong KK; Somlo G; Margolin K; Chow W; Sniecinski I; Vora N; Slovak M; Niland JC; Forman SJ
Clin Lymphoma; 2000 Jun; 1(1):46-54. PubMed ID: 11707813
[TBL] [Abstract][Full Text] [Related]
15. High-dose cyclophosphamide, carmustine (BCNU), and etoposide (VP16-213) with or without cisplatin (CBV +/- P) and autologous transplantation for patients with Hodgkin's disease who fail to enter a complete remission after combination chemotherapy.
Reece DE; Barnett MJ; Shepherd JD; Hogge DE; Klasa RJ; Nantel SH; Sutherland HJ; Klingemann HG; Fairey RN; Voss NJ
Blood; 1995 Jul; 86(2):451-6. PubMed ID: 7541661
[TBL] [Abstract][Full Text] [Related]
16. Double high-dose therapy for Hodgkin's disease with dose-intensive cyclophosphamide, etoposide, and cisplatin (DICEP) prior to high-dose melphalan and autologous stem cell transplantation.
Stewart DA; Guo D; Glück S; Morris D; Chaudhry A; deMetz C; Klassen J; Brown CB; Russell JA
Bone Marrow Transplant; 2000 Aug; 26(4):383-8. PubMed ID: 10982284
[TBL] [Abstract][Full Text] [Related]
17. Ifosfamide, etoposide, cytarabine, and dexamethasone as salvage treatment followed by high-dose cyclophosphamide, melphalan, and etoposide with autologous peripheral blood stem cell transplantation for relapsed or refractory lymphomas.
Schütt P; Passon J; Ebeling P; Welt A; Müller S; Metz K; Moritz T; Seeber S; Nowrousian MR
Eur J Haematol; 2007 Feb; 78(2):93-101. PubMed ID: 17313557
[TBL] [Abstract][Full Text] [Related]
18. Intensive therapy and autotransplantation in Hodgkin's disease.
Reece DE; Phillips GL
Stem Cells; 1994 Sep; 12(5):477-93. PubMed ID: 7804123
[TBL] [Abstract][Full Text] [Related]
19. Long-term follow-up in patients treated with Mini-BEAM as salvage therapy for relapsed or refractory Hodgkin's disease.
Martín A; Fernández-Jiménez MC; Caballero MD; Canales MA; Pérez-Simón JA; García de Bustos J; Vázquez L; Hernández-Navarro F; San Miguel JF
Br J Haematol; 2001 Apr; 113(1):161-71. PubMed ID: 11328296
[TBL] [Abstract][Full Text] [Related]
20. High-dose cyclophosphamide, carmustine, and etoposide followed by allogeneic bone marrow transplantation in patients with lymphoid malignancies who had received prior dose-limiting radiation therapy.
Demirer T; Weaver CH; Buckner CD; Petersen FB; Bensinger WI; Sanders J; Clift RA; Lilleby K; Anasetti C; Martin P
J Clin Oncol; 1995 Mar; 13(3):596-602. PubMed ID: 7884421
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]